KLINIK FOR FYSIOTERAPI NYBORG ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Bankruptcy risk for industry  0.6% 0.6% 0.6% 0.6% 0.6%  
Bankruptcy risk  1.9% 1.9% 1.9% 1.9% 2.1%  
Credit score (0-100)  69 69 70 69 67  
Credit rating  A A A A A  
Credit limit (kDKK)  0.2 0.3 0.4 0.3 0.1  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Gross profit  -7.0 16.3 5.5 22.2 13.8  
EBITDA  -13.0 10.8 -0.0 16.2 7.8  
EBIT  -13.0 10.8 -0.0 16.2 7.8  
Pre-tax profit (PTP)  -14.2 33.3 -13.0 54.3 95.1  
Net earnings  -11.1 25.9 -10.2 41.9 74.2  
Pre-tax profit without non-rec. items  -14.2 33.3 -13.0 54.3 95.1  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Tangible assets total  370 370 370 370 370  
Shareholders equity total  946 972 962 954 1,028  
Interest-bearing liabilities  133 138 133 34.7 37.3  
Balance sheet total (assets)  1,103 1,132 1,116 1,018 1,118  

Net Debt  -598 -623 -596 -600 -707  
 
See the entire balance sheet

Volume 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -7.0 16.3 5.5 22.2 13.8  
Gross profit growth  0.0% 0.0% -66.3% 303.4% -37.8%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,103 1,132 1,116 1,018 1,118  
Balance sheet change%  -1.5% 2.5% -1.4% -8.7% 9.8%  
Added value  -13.0 10.8 -0.0 16.2 7.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 1.0 -1.0 1.0 2.0  

Profitability 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  185.2% 66.3% -0.1% 72.9% 56.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -1.2% 3.1% 3.7% 5.1% 8.9%  
ROI %  -1.2% 3.1% 3.8% 5.2% 9.2%  
ROE %  -1.2% 2.7% -1.1% 4.4% 7.5%  

Solidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Equity ratio %  85.7% 85.9% 86.2% 93.7% 91.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  4,582.9% -5,763.9% 14,894,525.0% -3,711.8% -9,085.7%  
Gearing %  14.1% 14.2% 13.9% 3.6% 3.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.8% 0.6% 40.5% 0.1% 0.0%  

Liquidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Quick Ratio  5.1 5.2 5.3 12.5 9.6  
Current Ratio  5.1 5.2 5.3 12.5 9.6  
Cash and cash equivalent  730.5 760.8 729.1 634.9 744.6  

Capital use efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  38.8 64.7 109.2 63.0 52.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Net sales / employee  0 0 0 0 0  
Added value / employee  -13 11 -0 16 8  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -13 11 -0 16 8  
EBIT / employee  -13 11 -0 16 8  
Net earnings / employee  -11 26 -10 42 74